Navigation Links
Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System
Date:10/21/2008

Results to be displayed at CHEST meeting in October

BURLINGTON, Mass., Oct. 21 /PRNewswire/ -- Tomophase Corporation announced today that it will display the first in-vivo cross-sectional images of implanted pulmonary stents using their proprietary optical coherence tomography (OCT) system at the CHEST meeting in Philadelphia, Oct. 27th through Oct. 29th. The images were captured using the Tomophase OCT System as part of an ongoing research collaboration with Dr. Armin Ernst, Director of Interventional Pulmonology and Dr. Hisashi Tsukada, Research Associate, at Beth Israel Deaconess Medical Center in Boston, Massachusetts.

The Tomophase OCT System enables the interventional pulmonologist to clearly visualize sub-epithelial tissue structures in the airway. The system, which is not yet FDA-approved, utilizes a near-infrared emitting probe in a catheter which is integrated with a conventional video bronchoscope. The images captured by the research team at Beth Israel are from in-vivo animal model tracheal tissue. During the next several months, the company plans to continue this work as it progresses towards use of the system in human clinical studies.

"Our goal at Tomophase is to use our proprietary optical technology to help clinicians image subsurface pulmonary tissue at a level of resolution currently unavailable, while not exposing the patient to potentially harmful radiation, UV light or contrast agents," commented Dr. Peter Norris, CEO of Tomophase. "Much of the structure in the airways beneath the epithelial layer is essentially invisible to clinicians. Providing real-time access to this information could provide major benefits to both diagnostic and therapeutic approaches to many pulmonary diseases. We believe this research collaboration with Beth Israel Deaconess is an important first step in establishing the utility of this breakthrough technology in both research and the clinic."

"These latest imaging results from the Tomophase OCT system show excellent detail in the region surrounding the implanted stent," commented Dr. Ernst. "As such, it may ultimately prove very useful to clinicians in understanding the detailed nature of the interaction between the stent material, including those made from bio-absorbable materials, and the surrounding tissue. High-resolution, cross-sectional OCT imaging technology may also have the potential to provide real-time evaluation of other drug and device/tissue interactions as well."

About Tomophase Corporation

Tomophase Corporation is a private company founded in 2003 based on proprietary technology innovations in the field of optical coherence tomography and its use to image tissue at high resolution. With Tomophase OCT, researchers and clinicians can observe tissue structure within 2-3 mm of the surface without the use of radiation, UV light or image contrast agents. Tomophase is pursuing the first application of its technology in pulmonary medicine for the visualization of airways. Future development areas include respiratory therapy development, lung cancer management and surgical guidance.

More information on Tomophase Corporation can be found at http://www.tomophase.com.

For further information:

Dr. Peter Norris, CEO

Tomophase Corporation

1 North Ave., Burlington, MA 01803

P: (781) 229-5700 x122

E: pnorris@tompohase.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Tomophase Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
2. Worlds Largest Exhibit of Princess Dianas Dresses Hosted by Appleton Museum
3. Sesame Street Exhibition Makes Texas Premier at The Health Museum
4. CRH Medical to exhibit at American College of Surgeons Annual Clinical Congress
5. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
6. Global Med Technologies(R), Inc.s Division, Wyndgate Technologies(R), to Exhibit at 60th Annual AABB Conference
7. Our Body: The Universe Within Exhibition Announces Four New Exhibits Across The Nation
8. Inovis Sponsors ASC X12 Conference, Exhibits BizManager and Secure Link
9. Hooper Holmes to Exhibit at the 2007 Sixth Annual Association of Home Office Underwriters Conference
10. The Justin Gimelstob Childrens Fund Hosts Tennis Exhibition
11. NASA Astronauts, Exercise Exhibit To Be At Houston Marathon Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: